Dec 23 (Reuters) - Cancer therapy maker Legend Biotech's
Chief Financial Officer Lori Macomber has submitted her resignation notice to the company, a filing with the U.S. Securities and Exchange Commission showed on Monday.
Macomber, who was promoted to the CFO role in 2022, would step down due to personal reasons, effective Jan. 2, 2025, the filing added.
Insider Jessie Yeung has been appointed as the interim CFO and the board has designated her as company's interim principal financial officer.
(Reporting by Anuja Bharat Mistry in Bengaluru; Editing by Mohammed Safi Shamsi)
((AnujaBharat.Mistry@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.